H.B. 76 Enrolled

1

PHARMACY AUDIT RIGHTS
2 2012 GENERAL SESSION
3 STATE OF UTAH
4 Chief Sponsor: Evan J. Vickers
5 Senate Sponsor: Stephen H. Urquhart
6 Cosponsors:
7 Rebecca Chavez-Houck
8 Brad L. Dee
9 Richard A. Greenwood
10 Lynn N. Hemingway
11 Don L. Ipson
Bradley G. LastDaniel McCay
Ronda Rudd Menlove
Merlynn T. Newbold
Michael E. Noel
Dixon M. Pitcher
Paul RayDean Sanpei
V. Lowry Snow
Christine F. Watkins
R. Curt Webb
Brad R. Wilson 12
13 LONG TITLE
14 General Description:
15 This bill requires health benefit plans, the Public Employees' Benefits and Insurance
16 Program, and pharmacy benefit managers to implement certain pharmacy audit
17 procedures when auditing pharmacy claims.
18 Highlighted Provisions:
19 This bill:
20 . requires a health insurer and a pharmacy benefits manager for a health insurer to
21 comply with pharmacy audit rights established in the Pharmacy Practice Act;
22 . requires the Public Employees' Benefit and Insurance Program to comply with
23 pharmacy audit rights established in the Pharmacy Practice Act;
24 . amends the definition of pharmacy benefits manager in the Pharmacy Practice Act
25 to be consistent with the definition of pharmacy benefits manager in the Pharmacy
26 Benefits Manager Act; and
27 . enacts pharmacy audit rights in the Pharmacy Practices Act that include:

28 . definitions;
29 . requirements for notice of an audit;
30 . limits on the types of claims that may be audited; and
31 . requirements for an entity conducting an audit.
32 Money Appropriated in this Bill:
33 None
34 Other Special Clauses:
35 None
36 Utah Code Sections Affected:
37 AMENDS:
38 49-20-503, as enacted by Laws of Utah 2011, Chapter 83
39 58-17b-102, as last amended by Laws of Utah 2010, Chapter 101
40 ENACTS:
41 31A-22-640, Utah Code Annotated 1953
42 58-17b-622, Utah Code Annotated 1953
43
44 Be it enacted by the Legislature of the state of Utah:
45 Section 1. Section 31A-22-640 is enacted to read:
46 31A-22-640. Insurer and pharmacy benefit management services -- Audit
47 restrictions.
48 (1) For purposes of this section "pharmacy benefits manager or coordinator" means a
49 person or entity that provides pharmacy benefit management services as defined in Section
50 49-20-502 on behalf of an insurer as defined in Subsection 31A-22-636 (1).
51 (2) An insurer and an insurer's pharmacy benefits manager or coordinator is subject to
52 the pharmacy audit provisions of Section 58-17b-622 .
53 Section 2. Section 49-20-503 is amended to read:
54 49-20-503. Request for proposals for pharmacy benefits manager for Public
55 Employees' Benefit and Insurance Program.

56 (1) When the board issues a request for proposals for a pharmacy benefits manager to
57 provide pharmacy benefits management services for the program, the request for proposals
58 shall:
59 (a) require each responder to comply with the pharmacy audit provisions of Section
60 58-17b-622 ; and
61 (b) provide each responder with the option to include, among the billing options
62 proposed, a billing option that complies with the requirements described in this section.
63 (2) The billing option described in Subsection (1) shall require the pharmacy benefits
64 manager to, on at least a monthly basis, submit to the board an invoice for all pharmacy
65 services paid by the pharmacy benefits manager on behalf of the program since the last request
66 for payment or reimbursement.
67 (3) The invoice described in Subsection (2) shall state, as a separate item from any
68 other amount:
69 (a) the total amount due to the pharmacy benefits manager for all pharmacy services
70 billed in the invoice; and
71 (b) the total amount paid by the pharmacy benefits manager for the same pharmacy
72 services for which payment is sought in that invoice.
73 Section 3. Section 58-17b-102 is amended to read:
74 58-17b-102. Definitions.
75 In addition to the definitions in Section 58-1-102 , as used in this chapter:
76 (1) "Administering" means:
77 (a) the direct application of a prescription drug or device, whether by injection,
78 inhalation, ingestion, or by any other means, to the body of a human patient or research subject
79 by another person; or
80 (b) the placement by a veterinarian with the owner or caretaker of an animal or group
81 of animals of a prescription drug for the purpose of injection, inhalation, ingestion, or any other
82 means directed to the body of the animal by the owner or caretaker in accordance with written
83 or verbal directions of the veterinarian.

84 (2) "Adulterated drug or device" means a drug or device considered adulterated under
85 21 U.S.C.S. Sec. 351 (2003).
86 (3) (a) "Analytical laboratory" means a facility in possession of prescription drugs for
87 the purpose of analysis.
88 (b) "Analytical laboratory" does not include a laboratory possessing prescription drugs
89 used as standards and controls in performing drug monitoring or drug screening analysis if the
90 prescription drugs are prediluted in a human or animal body fluid, human or animal body fluid
91 components, organic solvents, or inorganic buffers at a concentration not exceeding one
92 milligram per milliliter when labeled or otherwise designated as being for in vitro diagnostic
93 use.
94 (4) "Animal euthanasia agency" means an agency performing euthanasia on animals by
95 the use of prescription drugs.
96 (5) "Automated pharmacy systems" includes mechanical systems which perform
97 operations or activities, other than compounding or administration, relative to the storage,
98 packaging, dispensing, or distribution of medications, and which collect, control, and maintain
99 all transaction information.
100 (6) "Beyond use date" means the date determined by a pharmacist and placed on a
101 prescription label at the time of dispensing that indicates to the patient or caregiver a time
102 beyond which the contents of the prescription are not recommended to be used.
103 [(8)] (7) "Board of pharmacy" or "board" means the Utah State Board of Pharmacy
104 created in Section 58-17b-201 .
105 [(7)] (8) "Branch pharmacy" means a pharmacy or other facility in a rural or medically
106 underserved area, used for the storage and dispensing of prescription drugs, which is dependent
107 upon, stocked by, and supervised by a pharmacist in another licensed pharmacy designated and
108 approved by the division as the parent pharmacy.
109 (9) "Centralized prescription processing" means the processing by a pharmacy of a
110 request from another pharmacy to fill or refill a prescription drug order or to perform
111 processing functions such as dispensing, drug utilization review, claims adjudication, refill

112 authorizations, and therapeutic interventions.
113 (10) "Class A pharmacy" means a pharmacy located in Utah that is authorized as a
114 retail pharmacy to compound or dispense a drug or dispense a device to the public under a
115 prescription order.
116 (11) "Class B pharmacy":
117 (a) means a pharmacy located in Utah:
118 (i) that is authorized to provide pharmaceutical care for patients in an institutional
119 setting; and
120 (ii) whose primary purpose is to provide a physical environment for patients to obtain
121 health care services; and
122 (b) (i) includes closed-door, hospital, clinic, nuclear, and branch pharmacies; and
123 (ii) pharmaceutical administration and sterile product preparation facilities.
124 (12) "Class C pharmacy" means a pharmacy located in Utah that is authorized to
125 engage in the manufacture, production, wholesale, or distribution of drugs or devices.
126 (13) "Class D pharmacy" means a nonresident pharmacy.
127 (14) "Class E pharmacy" means all other pharmacies.
128 (15) "Closed-door pharmacy" means a pharmacy that provides pharmaceutical care to a
129 defined and exclusive group of patients who have access to the services of the pharmacy
130 because they are treated by or have an affiliation with a specific entity, including a health
131 maintenance organization or an infusion company, but not including a hospital pharmacy, a
132 retailer of goods to the general public, or the office of a practitioner.
133 (16) "Collaborative pharmacy practice" means a practice of pharmacy whereby one or
134 more pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or
135 more practitioners under protocol whereby the pharmacist may perform certain pharmaceutical
136 care functions authorized by the practitioner or practitioners under certain specified conditions
137 or limitations.
138 (17) "Collaborative pharmacy practice agreement" means a written and signed
139 agreement between one or more pharmacists and one or more practitioners that provides for

140 collaborative pharmacy practice for the purpose of drug therapy management of patients and
141 prevention of disease of human subjects.
142 (18) (a) "Compounding" means the preparation, mixing, assembling, packaging, or
143 labeling of a limited quantity drug, sterile product, or device:
144 (i) as the result of a practitioner's prescription order or initiative based on the
145 practitioner, patient, or pharmacist relationship in the course of professional practice;
146 (ii) for the purpose of, or as an incident to, research, teaching, or chemical analysis and
147 not for sale or dispensing; or
148 (iii) in anticipation of prescription drug orders based on routine, regularly observed
149 prescribing patterns.
150 (b) "Compounding" does not include:
151 (i) the preparation of prescription drugs by a pharmacist or pharmacy intern for sale to
152 another pharmacist or pharmaceutical facility;
153 (ii) the preparation by a pharmacist or pharmacy intern of any prescription drug in a
154 dosage form which is regularly and commonly available from a manufacturer in quantities and
155 strengths prescribed by a practitioner; or
156 (iii) the preparation of a prescription drug, sterile product, or device which has been
157 withdrawn from the market for safety reasons.
158 (19) "Confidential information" has the same meaning as "protected health
159 information" under the Standards for Privacy of Individually Identifiable Health Information,
160 45 C.F.R. Parts 160 and 164.
161 (20) "Controlled substance" has the same definition as in Section 58-37-2 .
162 (21) "Dietary supplement" has the same meaning as Public Law Title 103, Chapter
163 417, Sec. 3a(ff) which is incorporated by reference.
164 (22) "Dispense" means the interpretation, evaluation, and implementation of a
165 prescription drug order or device or nonprescription drug or device under a lawful order of a
166 practitioner in a suitable container appropriately labeled for subsequent administration to or use
167 by a patient, research subject, or an animal.

168 (23) "Distribute" means to deliver a drug or device other than by administering or
169 dispensing.
170 (24) (a) "Drug" means:
171 (i) a substance recognized in the official United States Pharmacopoeia, Official
172 Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
173 supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
174 prevention of disease in humans or animals;
175 (ii) a substance that is required by any applicable federal or state law or rule to be
176 dispensed by prescription only or is restricted to administration by practitioners only;
177 (iii) a substance other than food intended to affect the structure or any function of the
178 body of humans or other animals; and
179 (iv) substances intended for use as a component of any substance specified in
180 Subsections (24)(a)(i), (ii), (iii), and (iv).
181 (b) "Drug" does not include dietary supplements.
182 (25) "Drug product equivalent" means a drug product that is designated as the
183 therapeutic equivalent of another drug product in the Approved Drug Products with
184 Therapeutic Equivalence Evaluations prepared by the Center for Drug Evaluation and Research
185 of the Federal Food and Drug Administration.
186 (26) "Drug regimen review" includes the following activities:
187 (a) evaluation of the prescription drug order and patient record for:
188 (i) known allergies;
189 (ii) rational therapy-contraindications;
190 (iii) reasonable dose and route of administration; and
191 (iv) reasonable directions for use;
192 (b) evaluation of the prescription drug order and patient record for duplication of
193 therapy;
194 (c) evaluation of the prescription drug order and patient record for the following
195 interactions:

196 (i) drug-drug;
197 (ii) drug-food;
198 (iii) drug-disease; and
199 (iv) adverse drug reactions; and
200 (d) evaluation of the prescription drug order and patient record for proper utilization,
201 including over- or under-utilization, and optimum therapeutic outcomes.
202 (27) "Drug sample" means a prescription drug packaged in small quantities consistent
203 with limited dosage therapy of the particular drug, which is marked "sample", is not intended to
204 be sold, and is intended to be provided to practitioners for the immediate needs of patients for
205 trial purposes or to provide the drug to the patient until a prescription can be filled by the
206 patient.
207 (28) "Electronic signature" means a trusted, verifiable, and secure electronic sound,
208 symbol, or process attached to or logically associated with a record and executed or adopted by
209 a person with the intent to sign the record.
210 (29) "Electronic transmission" means transmission of information in electronic form or
211 the transmission of the exact visual image of a document by way of electronic equipment.
212 (30) "Extern" means a college of pharmacy student enrolled in a college coordinated
213 practical experience program in a health care setting under the supervision of a preceptor, as
214 defined in this act, and approved by a college of pharmacy.
215 (31) "Hospital pharmacy" means a pharmacy providing pharmaceutical care to
216 inpatients of a general acute hospital or specialty hospital licensed by the Department of Health
217 under Title 26, Chapter 21, Health Care Facility Licensing and Inspection Act.
218 (32) "Legend drug" has the same meaning as prescription drug.
219 (33) "Licensed pharmacy technician" means an individual licensed with the division,
220 that may, under the supervision of a pharmacist, perform the activities involved in the
221 technician practice of pharmacy.
222 (34) "Manufacturer" means a person or business physically located in Utah licensed to
223 be engaged in the manufacturing of drugs or devices.

224 (35) (a) "Manufacturing" means:
225 (i) the production, preparation, propagation, conversion, or processing of a drug or
226 device, either directly or indirectly, by extraction from substances of natural origin or
227 independently by means of chemical or biological synthesis, or by a combination of extraction
228 and chemical synthesis, and includes any packaging or repackaging of the substance or labeling
229 or relabeling of its container; and
230 (ii) the promotion and marketing of such drugs or devices.
231 (b) "Manufacturing" includes the preparation and promotion of commercially available
232 products from bulk compounds for resale by pharmacies, practitioners, or other persons.
233 (c) "Manufacturing" does not include the preparation or compounding of a drug by a
234 pharmacist, pharmacy intern, or practitioner for that individual's own use or the preparation,
235 compounding, packaging, labeling of a drug, or incident to research, teaching, or chemical
236 analysis.
237 (36) "Medical order" means a lawful order of a practitioner which may include a
238 prescription drug order.
239 (37) "Medication profile" or "profile" means a record system maintained as to drugs or
240 devices prescribed for a pharmacy patient to enable a pharmacist or pharmacy intern to analyze
241 the profile to provide pharmaceutical care.
242 (38) "Misbranded drug or device" means a drug or device considered misbranded under
243 21 U.S.C.S. Sec. 352 (2003).
244 (39) (a) "Nonprescription drug" means a drug which:
245 (i) may be sold without a prescription; and
246 (ii) is labeled for use by the consumer in accordance with federal law.
247 (b) "Nonprescription drug" includes homeopathic remedies.
248 (40) "Nonresident pharmacy" means a pharmacy located outside of Utah that sells to a
249 person in Utah.
250 (41) "Nuclear pharmacy" means a pharmacy providing radio-pharmaceutical service.
251 (42) "Out-of-state mail service pharmacy" means a pharmaceutical facility located

252 outside the state that is licensed and in good standing in another state, that:
253 (a) ships, mails, or delivers by any lawful means a dispensed legend drug to a patient in
254 this state pursuant to a lawfully issued prescription;
255 (b) provides information to a patient in this state on drugs or devices which may
256 include, but is not limited to, advice relating to therapeutic values, potential hazards, and uses;
257 or
258 (c) counsels pharmacy patients residing in this state concerning adverse and therapeutic
259 effects of drugs.
260 (43) "Patient counseling" means the written and oral communication by the pharmacist
261 or pharmacy intern of information, to the patient or caregiver, in order to ensure proper use of
262 drugs, devices, and dietary supplements.
263 (44) "Pharmaceutical administration facility" means a facility, agency, or institution in
264 which:
265 (a) prescription drugs or devices are held, stored, or are otherwise under the control of
266 the facility or agency for administration to patients of that facility or agency;
267 (b) prescription drugs are dispensed to the facility or agency by a licensed pharmacist
268 or pharmacy intern with whom the facility has established a prescription drug supervising
269 relationship under which the pharmacist or pharmacy intern provides counseling to the facility
270 or agency staff as required, and oversees drug control, accounting, and destruction; and
271 (c) prescription drugs are professionally administered in accordance with the order of a
272 practitioner by an employee or agent of the facility or agency.
273 (45) (a) "Pharmaceutical care" means carrying out the following in collaboration with a
274 prescribing practitioner, and in accordance with division rule:
275 (i) designing, implementing, and monitoring a therapeutic drug plan intended to
276 achieve favorable outcomes related to a specific patient for the purpose of curing or preventing
277 the patient's disease;
278 (ii) eliminating or reducing a patient's symptoms; or
279 (iii) arresting or slowing a disease process.

280 (b) "Pharmaceutical care" does not include prescribing of drugs without consent of a
281 prescribing practitioner.
282 (46) "Pharmaceutical facility" means a business engaged in the dispensing, delivering,
283 distributing, manufacturing, or wholesaling of prescription drugs or devices within or into this
284 state.
285 (47) (a) "Pharmaceutical wholesaler or distributor" means a pharmaceutical facility
286 engaged in the business of wholesale vending or selling of any prescription drug or device to
287 other than the consumer or user of the prescription drug or device, which the pharmaceutical
288 facility has not produced, manufactured, compounded, or dispensed.
289 (b) "Pharmaceutical wholesaler or distributor" does not include a pharmaceutical
290 facility carrying out the following business activities:
291 (i) intracompany sales;
292 (ii) the sale, purchase, or trade of a prescription drug or device, or offer to sell,
293 purchase or trade a prescription drug or device between hospitals or other health care facilities
294 that are under common ownership or control of the management and operation of the facilities;
295 (iii) the sale, purchase, or trade of a prescription drug or device, or offer to sell,
296 purchase, or trade a prescription drug or device for emergency medical reasons, or to supply
297 another pharmaceutical facility to alleviate a temporary shortage; or
298 (iv) the distribution of a prescription drug or device as a sample by representatives of a
299 manufacturer.
300 (48) "Pharmacist" means an individual licensed by this state to engage in the practice
301 of pharmacy.
302 (49) "Pharmacist-in-charge" means a pharmacist currently licensed in good standing
303 who accepts responsibility for the operation of a pharmacy in conformance with all laws and
304 rules pertinent to the practice of pharmacy and the distribution of drugs, and who is personally
305 in full and actual charge of the pharmacy and all personnel.
306 (50) "Pharmacist preceptor" means a licensed pharmacist in good standing with two or
307 more years of licensed experience. The preceptor serves as a teacher, example of professional

308 conduct, and supervisor of interns in the professional practice of pharmacy.
309 (51) "Pharmacy" means any place where:
310 (a) drugs are dispensed;
311 (b) pharmaceutical care is provided;
312 (c) drugs are processed or handled for eventual use by a patient; or
313 (d) drugs are used for the purpose of analysis or research.
314 (52) "Pharmacy benefits manager or coordinator" means a person or entity that
315 [administers the prescription drug or device portion of a health insurance plan] provides
316 pharmacy benefit management services as defined in Section 49-20-502 on behalf of a
317 self-insured employer, insurance company, health maintenance organization, or other plan
318 sponsor, as defined by rule.
319 (53) "Pharmacy intern" means an individual licensed by this state to engage in practice
320 as a pharmacy intern.
321 (54) "Pharmacy technician training program" means an approved technician training
322 program providing education for pharmacy technicians.
323 (55) (a) "Practice as a licensed pharmacy technician" means engaging in practice as a
324 pharmacy technician under the general supervision of a licensed pharmacist and in accordance
325 with a scope of practice defined by division rule made in collaboration with the board.
326 (b) "Practice as a licensed pharmacy technician" does not include:
327 (i) performing a drug utilization review, prescription drug order clarification from a
328 prescriber, final review of the prescription and prescribed drug prepared for dispensing,
329 dispensing of the drug, or counseling a patient with respect to a prescription drug;
330 (ii) counseling regarding nonprescription drugs and dietary supplements unless
331 delegated by the supervising pharmacist; or
332 (iii) receiving new prescription drug orders when communicating telephonically or
333 electronically unless the original information is recorded so the pharmacist may review the
334 prescription drug order as transmitted.
335 (56) "Practice of pharmacy" includes the following:

336 (a) providing pharmaceutical care;
337 (b) collaborative pharmacy practice in accordance with a collaborative pharmacy
338 practice agreement;
339 (c) compounding, packaging, labeling, dispensing, administering, and the coincident
340 distribution of prescription drugs or devices, provided that the administration of a prescription
341 drug or device is:
342 (i) pursuant to a lawful order of a practitioner when one is required by law; and
343 (ii) in accordance with written guidelines or protocols:
344 (A) established by the licensed facility in which the prescription drug or device is to be
345 administered on an inpatient basis; or
346 (B) approved by the division, in collaboration with the board and the Physicians
347 Licensing Board, created in Section 58-67-201 , if the prescription drug or device is to be
348 administered on an outpatient basis solely by a licensed pharmacist;
349 (d) participating in drug utilization review;
350 (e) ensuring proper and safe storage of drugs and devices;
351 (f) maintaining records of drugs and devices in accordance with state and federal law
352 and the standards and ethics of the profession;
353 (g) providing information on drugs or devices, which may include advice relating to
354 therapeutic values, potential hazards, and uses;
355 (h) providing drug product equivalents;
356 (i) supervising pharmacist's supportive personnel, pharmacy interns, and pharmacy
357 technicians;
358 (j) providing patient counseling, including adverse and therapeutic effects of drugs;
359 (k) providing emergency refills as defined by rule;
360 (l) telepharmacy; and
361 (m) formulary management intervention.
362 (57) "Practice of telepharmacy" means the practice of pharmacy through the use of
363 telecommunications and information technologies.

364 (58) "Practice of telepharmacy across state lines" means the practice of pharmacy
365 through the use of telecommunications and information technologies that occurs when the
366 patient is physically located within one jurisdiction and the pharmacist is located in another
367 jurisdiction.
368 (59) "Practitioner" means an individual currently licensed, registered, or otherwise
369 authorized by the appropriate jurisdiction to prescribe and administer drugs in the course of
370 professional practice.
371 (60) "Prescribe" means to issue a prescription:
372 (a) orally or in writing; or
373 (b) by telephone, facsimile transmission, computer, or other electronic means of
374 communication as defined by division rule.
375 (61) "Prescription" means an order issued:
376 (a) by a licensed practitioner in the course of that practitioner's professional practice or
377 by collaborative pharmacy practice agreement; and
378 (b) for a controlled substance or other prescription drug or device for use by a patient
379 or an animal.
380 (62) "Prescription device" means an instrument, apparatus, implement, machine,
381 contrivance, implant, in vitro reagent, or other similar or related article, and any component
382 part or accessory, which is required under federal or state law to be prescribed by a practitioner
383 and dispensed by or through a person or entity licensed under this chapter or exempt from
384 licensure under this chapter.
385 (63) "Prescription drug" means a drug that is required by federal or state law or rule to
386 be dispensed only by prescription or is restricted to administration only by practitioners.
387 (64) "Retail pharmacy" means a pharmaceutical facility dispensing prescription drugs
388 and devices to the general public.
389 (65) "Self-audit" means an internal evaluation of a pharmacy to determine compliance
390 with this chapter.
391 (66) "Supervising pharmacist" means a pharmacist who is overseeing the operation of

392 the pharmacy during a given day or shift.
393 (67) "Supportive personnel" means unlicensed individuals who:
394 (a) may assist a pharmacist, pharmacist preceptor, pharmacy intern, or licensed
395 pharmacy technician in nonjudgmental duties not included in the definition of the practice of
396 pharmacy, practice of a pharmacy intern, or practice of a licensed pharmacy technician, and as
397 those duties may be further defined by division rule adopted in collaboration with the board;
398 and
399 (b) are supervised by a pharmacist in accordance with rules adopted by the division in
400 collaboration with the board.
401 (68) "Unlawful conduct" is as defined in Sections 58-1-501 and 58-17b-501 .
402 (69) "Unprofessional conduct" is as defined in Sections 58-1-501 and 58-17b-502 and
403 may be further defined by rule.
404 (70) "Veterinary pharmaceutical facility" means a pharmaceutical facility that
405 dispenses drugs intended for use by animals or for sale to veterinarians for the administration
406 for animals.
407 Section 4. Section 58-17b-622 is enacted to read:
408 58-17b-622. Pharmacy benefit management services -- Auditing of pharmacy
409 records -- Appeals.
410 (1) For purposes of this section:
411 (a) "Audit" means a review of the records of a pharmacy by or on behalf of an entity
412 that finances or reimburses the cost of health care services or pharmaceutical products.
413 (b) "Entity" includes:
414 (i) a pharmacy benefits manager or coordinator;
415 (ii) a health benefit plan;
416 (iii) a third party administrator as defined in Section 31A-1-301 ;
417 (iv) a state agency; or
418 (v) a company, group, or agent that represents, or is engaged by, one of the entities
419 described in Subsections (1)(b)(i) through (iv).

420 (c) "Fraud" means an intentional act of deception, misrepresentation, or concealment in
421 order to gain something of value.
422 (d) "Health benefit plan" means:
423 (i) a health benefit plan as defined in Section 31A-1-301 ; or
424 (ii) a health, dental, medical, Medicare supplement, or conversion program offered
425 under Title 49, Chapter 20, Public Employees' Benefit and Insurance Program Act.
426 (2) (a) Except as provided in Subsection (2)(b), this section applies to:
427 (i) a contract for the audit of a pharmacy entered into, amended, or renewed on or after
428 July 1, 2012; and
429 (ii) an entity that conducts an audit of the pharmacy records of a pharmacy licensed
430 under this chapter.
431 (b) This section does not apply to an audit of pharmacy records:
432 (i) for a federally funded prescription drug program, including:
433 (A) the state Medicaid program;
434 (B) the Medicare Part D program;
435 (C) a Department of Defense prescription drug program;
436 (D) a Veteran's Affairs prescription drug program; or
437 (ii) when fraud or other intentional and willful misrepresentation is alleged and the
438 pharmacy audit entity has evidence that the pharmacy's actions reasonably indicate fraud or
439 intentional and willful misrepresentation.
440 (3) (a) An audit that involves clinical or professional judgment shall be conducted by
441 or in consultation with a licensed pharmacist who is employed by or working with the auditing
442 entity.
443 (b) If an audit is conducted on site at a pharmacy, the entity conducting the audit:
444 (i) shall give the pharmacy 10 days advanced written notice of:
445 (A) the audit; and
446 (B) the range of prescription numbers or a date range included in the audit; and
447 (ii) may not audit a pharmacy during the first five business days of the month, unless

448 the pharmacy agrees to the timing of the audit.
449 (c) An entity may not audit claims:
450 (i) submitted more than 18 months prior to the audit, unless:
451 (A) required by federal law; or
452 (B) the originating prescription is dated in the preceding six months; or
453 (ii) that exceed 200 selected prescription claims.
454 (4) (a) An entity may not:
455 (i) include dispensing fees in the calculations of overpayments unless the prescription
456 is considered a misfill;
457 (ii) recoup funds for prescription clerical or recordkeeping errors, including
458 typographical errors, scrivener's errors, and computer errors on a required document or record
459 unless the audit entity is alleging fraud or other intentional or willful misrepresentation and the
460 audit entity has evidence that the pharmacy's actions reasonably indicate fraud or intentional
461 and willful misrepresentation; or
462 (iii) collect any funds, charge-backs, or penalties until the audit and all appeals are
463 final, unless the audit entity is alleging fraud or other intentional or willful misrepresentation
464 and the audit entity has evidence that the pharmacy's actions reasonably indicate fraud or
465 intentional and willful misrepresentation.
466 (b) Auditors shall only have access to previous audit reports on a particular pharmacy
467 if the previous audit was conducted by the same entity except as required for compliance with
468 state or federal law.
469 (5) A pharmacy subject to an audit may use the following records to validate a claim
470 for a prescription, refill, or change in a prescription:
471 (a) electronic or physical copies of records of a health care facility, or a health care
472 provider with prescribing authority; and
473 (b) any prescription that complies with state law.
474 (6) (a) An entity that audits a pharmacy shall provide the pharmacy with a preliminary
475 audit report, delivered to the pharmacy or its corporate office of record within 60 days after

476 completion of the audit.
477 (b) A pharmacy has 30 days following receipt of the preliminary audit report to
478 respond to questions, provide additional documentation, and comment on and clarify findings
479 of the audit. Receipt of the report shall be based on the postmark date or the date of a
480 computer transmission if transferred electronically.
481 (7) If an audit results in the dispute or denial of a claim, the entity conducting the audit
482 shall allow the pharmacy to resubmit a claim using any commercially reasonable method,
483 including fax, mail, or electronic claims submission provided that the period of time when a
484 claim may be resubmitted has not expired under the rules of the plan sponsor.
485 (8) (a) Within 120 days after the completion of the appeals process under Subsection
486 (9), a final audit report shall be delivered to the pharmacy or its corporate office of record.
487 (b) The final audit report shall include a disclosure of any money recovered by the
488 entity that conducted the audit.
489 (9) An entity that audits a pharmacy shall establish a written appeals process for
490 appealing a preliminary audit report and a final audit report, and shall provide the pharmacy
491 with notice of the written appeals process. If the pharmacy benefit manager's contract or
492 provider manual contains the information required by this Subsection (9), the requirement for
493 notice is met.